caa a22 4500 605491240 CHVBK 20210128100509.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s10147-014-0764-5 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0764-5 Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma [Elektronische Daten] [Masahiro Nozawa, Takayuki Ohzeki, Satoshi Tamada, Fumiya Hongo, Satoshi Anai, Kiyohide Fujimoto, Tsuneharu Miki, Tatsuya Nakatani, Satoshi Fukasawa, Hirotsugu Uemura] Background: There have been few reports of the differences in safety between the mammalian target of rapamycin inhibitors, everolimus and temsirolimus. The purpose of this study is to compare the adverse event profiles of both agents and to estimate the risk factors for non-infectious pneumonitis in patients with advanced renal cell carcinoma on the basis of our real-world clinical experience. Methods: Data from 218 consecutive patients that received either everolimus or temsirolimus for advanced renal cell carcinoma at five Japanese centers were retrospectively analyzed. Chi-squared test and univariate and multivariate logistic regression analyses were performed to investigate the differences in adverse event profiles and the risk factors associated with non-infectious pneumonitis, respectively. Results: A total of 196 patients were evaluable. In the everolimus group compared with temsirolimus, stomatitis (56 vs 30%, p<0.001) and non-infectious pneumonitis (38 vs 22%, p=0.018) were more frequently observed, and asthenia (11 vs 23%, p=0.027), rash (20 vs 36%, p=0.018), and fatigue (33 vs 48%, p=0.032) occurred less frequently in all grades. On multivariate analysis, male gender (odds ratio3.65; 95% confidence interval 1.44-9.26, p=0.007) and everolimus treatment (odds ratio2.00; 95% confidence interval 1.01-3.96, p=0.046) were significantly associated with development of non-infectious pneumonitis. Conclusion: Our findings suggest that adverse event profiles may differ between everolimus and temsirolimus and that non-infectious pneumonitis may occur more frequently in patients treated with everolimus than temsirolimus. Further investigations are needed to confirm these results. Japan Society of Clinical Oncology, 2014 Adverse event nationallicence Everolimus nationallicence Mammalian target of rapamycin nationallicence Pneumonitis nationallicence Renal cell carcinoma nationallicence Temsirolimus nationallicence Nozawa Masahiro Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut Ohzeki Takayuki Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, 260-0801, Chiba, Japan aut Tamada Satoshi Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, 545-8585, Osaka, Japan aut Hongo Fumiya Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kamigyo-ku, 602-0841, Kyoto, Japan aut Anai Satoshi Department of Urology, Nara Medical University, 840 Shijocho, 634-0813, Kashihara, Nara, Japan aut Fujimoto Kiyohide Department of Urology, Nara Medical University, 840 Shijocho, 634-0813, Kashihara, Nara, Japan aut Miki Tsuneharu Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kamigyo-ku, 602-0841, Kyoto, Japan aut Nakatani Tatsuya Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, 545-8585, Osaka, Japan aut Fukasawa Satoshi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, 260-0801, Chiba, Japan aut Uemura Hirotsugu Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 790-795 1341-9625 20:4<790 2015 20 10147 https://doi.org/10.1007/s10147-014-0764-5 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0764-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nozawa Masahiro Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut NATIONALLICENCE 700 1- Ohzeki Takayuki Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, 260-0801, Chiba, Japan aut NATIONALLICENCE 700 1- Tamada Satoshi Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Hongo Fumiya Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kamigyo-ku, 602-0841, Kyoto, Japan aut NATIONALLICENCE 700 1- Anai Satoshi Department of Urology, Nara Medical University, 840 Shijocho, 634-0813, Kashihara, Nara, Japan aut NATIONALLICENCE 700 1- Fujimoto Kiyohide Department of Urology, Nara Medical University, 840 Shijocho, 634-0813, Kashihara, Nara, Japan aut NATIONALLICENCE 700 1- Miki Tsuneharu Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kamigyo-ku, 602-0841, Kyoto, Japan aut NATIONALLICENCE 700 1- Nakatani Tatsuya Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Fukasawa Satoshi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, 260-0801, Chiba, Japan aut NATIONALLICENCE 700 1- Uemura Hirotsugu Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 790-795 1341-9625 20:4<790 2015 20 10147